

September 3, 2025

Acyclovir Injection, USP 500 mg per 10 mL (50 mg per mL) **US-Approved Product – Now Available**

Dear Valued Customer,

To help mitigate a drug shortage situation in Canada, Health Canada has permitted the importation and release of **Fresenius Kabi's US-approved Acyclovir Injection, USP 500 mg per 10 mL (50 mg per mL)**.

Healthcare professionals should note that there are a few **clinical differences** (for e.g., additional indications for US-approved product, reconstitution technique, product packaging) between the currently approved Canadian product and the product being supplied. Please refer to the following important information:

1. The Canadian Product Monograph for prescribing information.
2. Risk Communication Letter dated September 2, 2025, describing details and clinical differences between the Canadian and the US-approved Acyclovir Injection products.

The Risk Communication Letter and product monograph can be conveniently located on the Fresenius Kabi Canada website at <https://www.fresenius-kabi.com/en-ca/>.

This product will be available to all customers with no restrictions and accessible as of **September 9, 2025**, at Ontario distribution centres, and on **September 10, 2025**, at all other distribution centres.

Fresenius Kabi Product Code	MDP Product Code	New MSD Product Code	McKesson Product Code	Product Description	Pack Size	Availability Date
622010	981400	1000848	201602	Fresenius Kabi's US-approved Acyclovir Injection, USP 500 mg per 10 mL (50 mg per mL)	10	At Ontario distribution centres: Sep. 9, 2025 At all other distribution centres: Sep. 10, 2025

If you have any questions or for more information, please contact your Sales Representative or our Customer Service Department at: Canada_CustomerService@Fresenius-Kabi.com or (877) 821-7724.

Sincerely,



Joseph Le
Associate Director, IV Drugs
joseph.le@fresenius-kabi.com

Please scan the QR code to sign up for our email communications.

